Lauren Riker - 30 Jan 2026 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Senior Vice President, Finance
Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
30 Jan 2026
Net transactions value
-$139,746
Form type
4
Filing time
03 Feb 2026, 18:24:09 UTC
Previous filing
06 Jan 2026
Next filing
13 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RIKER LAUREN Senior Vice President, Finance C/O PACIRA BIOSCIENCES, INC., 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE /s/ Kristen Williams, Attorney-in-Fact 03 Feb 2026 0001545439

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Tax liability $56,506 -2,751 -4.7% $20.54 56,313 30 Jan 2026 Direct F1
transaction PCRX Common Stock Sale $83,240 -4,000 -7.1% $20.81 52,313 02 Feb 2026 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.35 to $21.28, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3.